Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) ##STR00001##
including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, R.sup.5, R.sup.6a, R.sup.6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

It was discovered that a cyclic sulfamidate can be produced by reacting an amino acid derivative with a cyclization reagent. In addition, it was discovered that an O-substituted serine derivative can be produced by reacting a cyclic sulfamidate with an alcohol.

It was discovered that a cyclic sulfamidate can be produced by reacting an amino acid derivative with a cyclization reagent. In addition, it was discovered that an O-substituted serine derivative can be produced by reacting a cyclic sulfamidate with an alcohol.

A method of treating medium chain acyl-CoA dehydrogenase deficiency, very long chain acyl-CoA dehydrogenase deficiency, long chain hydroxyacyl-CoA dehydrogenase deficiency, trifunctional protein deficiency, or CPT II deficiency in a patient is provided comprising administering to the patient a therapeutic amount of a triglyceride or other conjugated fatty acid that bypasses or leads to an intermediate that bypasses the deficient enzyme. Amino acid-conjugated fatty acids also are provided as well as compositions comprising the amino acid-conjugated fatty acids.

In one aspect, the invention relates to compounds having the formula XII: ##STR00001##
where R.sup.a, R.sup.b, R.sup.2, R.sup.7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

In one aspect, the invention relates to compounds having the formula XII: ##STR00001##
where R.sup.a, R.sup.b, R.sup.2, R.sup.7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

The present invention relates to cocrystals of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol and a zwitterion coformer, processes for their preparation, and their use as a medicament and for the purification of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol. The invention also relates to compositions comprising the cocrystal.

The present invention relates to cocrystals of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol and a zwitterion coformer, processes for their preparation, and their use as a medicament and for the purification of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol. The invention also relates to compositions comprising the cocrystal.

Esterquats find major applications as fabric softeners. After Tallow fatty acids and Palm oil fatty acids, fatty acids from sustainable sources like Rice bran fatty acids (RBFA) are desired. RBFA is formed as a by-product during refining of Rice bran oil and hence it is contained in the non edible portion of the oil. The production of high quality esterquats from this by-product is challenging, but the invention describes a process to produce high quality esterquats having low odour and a low acid value. This enhances easy formulation of various products and better customer acceptance. Liquid esterquats produced from RBFA enable e.g. cold processing for fabric softener formulations.

Esterquats find major applications as fabric softeners. After Tallow fatty acids and Palm oil fatty acids, fatty acids from sustainable sources like Rice bran fatty acids (RBFA) are desired. RBFA is formed as a by-product during refining of Rice bran oil and hence it is contained in the non edible portion of the oil. The production of high quality esterquats from this by-product is challenging, but the invention describes a process to produce high quality esterquats having low odour and a low acid value. This enhances easy formulation of various products and better customer acceptance. Liquid esterquats produced from RBFA enable e.g. cold processing for fabric softener formulations.